Annette F. Favorite - 17 Feb 2026 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Role
Sr. VP & Chief HR Officer
Signature
/s/ Louis Lalli, as an agent for Annette Favorite
Issuer symbol
WST
Transactions as of
17 Feb 2026
Net transactions value
-$45,463
Form type
4
Filing time
19 Feb 2026, 18:58:47 UTC
Previous filing
20 Feb 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Favorite Annette F Sr. VP & Chief HR Officer 530 HERMAN O. WEST DRIVE, EXTON /s/ Louis Lalli, as an agent for Annette Favorite 19 Feb 2026 0001654975

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WST Common Stock Award $0 +442 +2.6% $0.000000 17,425 17 Feb 2026 Direct F1
transaction WST Common Stock Tax liability $36,586 -150 -0.86% $243.19 17,275 17 Feb 2026 Direct
transaction WST Common Stock Options Exercise +135 +0.78% 17,410 18 Feb 2026 Direct F2
transaction WST Common Stock Tax liability $8,877 -36 -0.21% $248.26 17,374 18 Feb 2026 Direct
holding WST Common Stock 4,962 17 Feb 2026 Non-Qualified Deferred Compensation Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WST Rst. Stock Unit Options Exercise $0 -135 -25% $0.000000 408 18 Feb 2026 Common Stock 135 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 On February 18, 2025, the reporting person was granted 542 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).